Skip to main content
Tech.euFundingExplorerBeta

Sigrid Therapeutics

Sigrid Therapeutics is developing an ingested medical device for lowering blood sugar in prediabetics.

Sigrid Therapeutics has raised €12M across 3 funding rounds from 9 investors, most recently a round in Jan 2026. Based in Stockholm, Sweden; active in Healthtech. Data as of 28 Oct 2026.

Total raised
€12M
€12,041,007
Funding rounds
3
Investors
9
distinct backers
Active since
2021-11
latest 2026-01

Funding by year

EUR raised per year · 2026 YTD
Sigrid Therapeutics — funding by year — interactive chart.
Data table
Sigrid Therapeutics — funding by year
2021€7.2M
2023€536k
2026€4.3M

Signals

Medium confidence
Raise-next likelihood43
base rate 30% for Other
  • ▲ In typical raise window
  • ▲ Up-round momentum
Exit likelihood10
base rate 11% (2+ rounds)
  • ▲ 5y since founding (typical exit age)
  • ▼ No recent equity round (debt-only or quiet)

Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

3 rounds
DateStageAmountInvestors
2026-01-07Other€4.3Mundisclosed investorsView deal →
2023-01-17Other€536kMattias Ankarberg,Private InvestorsView deal →
2021-11-10Other€7.2MBarbara Bergström,Crosslight Partners,Hans Bergström,Irrus Investments,Joyance Partners,Matsson familyView deal →

Similar companies

same sector or country

Global coverage: FundingData